MARKET

NKGN

NKGN

NKGen Biotech Inc
EXMKT
0.012
NaN%
Closed 09:30 10/02 EDT
OPEN
--
PREV CLOSE
0.011
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
4.060
52 WEEK LOW
0.0003
MARKET CAP
1.57M
P/E (TTM)
-0.0110
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NKGN last week (0921-0925)?
Weekly Report · 6d ago
Weekly Report: what happened at NKGN last week (0914-0918)?
Weekly Report · 09/21 09:18
NKGen Biotech to Present on Troculeucel for Neurodegenerative Diseases at 4th Great Bay Cell and Gene Therapy Forum
Barchart · 09/15 07:05
Weekly Report: what happened at NKGN last week (0907-0911)?
Weekly Report · 09/14 09:19
NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026
Barchart · 09/10 07:05
Weekly Report: what happened at NKGN last week (0831-0904)?
Weekly Report · 09/07 09:18
NKGen Biotech Expands Financing Through Convertible Note Issuance
TipRanks · 09/02 21:59
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Aug 2026
Seeking Alpha · 09/02 14:15
More
About NKGN
NKGen Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapeutics. Its product candidates are based on a manufacturing and cryopreservation process, which produces SuperNK (SNK) cells. SNK cells can be produced in large quantities and cryopreserved, while maintaining high levels of cytotoxicity and activating receptor expression after thawing and reconstitution. It is developing SNK01, an autologous natural killer (NK) cell therapy, for the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). Its autologous NK cell therapy candidate has clinical trials in several therapeutic areas, including oncology and neurodegeneration. SNK02 is its allogeneic NK cell product candidate. It is conducting clinical trials with its SNK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).

Webull offers NKGen Biotech Inc stock information, including EXMKT: NKGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKGN stock methods without spending real money on the virtual paper trading platform.